Biosimilar uptake in public hospitals: NHS Hospitals
By Danélia Botes
January 25, 2023
The Role of Time in Biosimilar Uptake
Biosimilars are gaining traction in the healthcare industry, with their use reaching 50% or more in public hospitals within three years of their first introduction. However, the uptake of these medical products varies greatly, with some hospitals fully embracing biosimilars, while others show little to no use. This article explores the uptake of biosimilars in public hospitals, providing an in-depth analysis based on recent research.
In the last decade, health systems have been challenged by the market entry of new drugs with high prices. In 2021 biologic drugs accounted for 78.6 billion euros in spending, and 34% of drug expenditures in Europe. Among these, 80% of the main nine therapy classes were exposed to biosimilar competition. This longitudinal analysis of Portuguese NHS hospitals shows that if all NHS hospitals had biosimilar shares equal to the highest ones, potential annual savings could reach 13.9 million euros.
Factors Influencing Biosimilar Adoption
Several factors influence the adoption of biosimilars in public hospitals. These include the type of drug, the hospital’s relationship with pharmaceutical companies, and the hospital’s financial situation. Interestingly, hospitals with higher debts were not more likely to adopt biosimilars, contrary to expectations. Time plays a crucial role in the adoption of biosimilars. As physicians and patients gain experience with these treatments, their use tends to increase. This trend suggests that education and communication efforts could significantly influence biosimilar uptake.
Despite the potential savings that biosimilars offer, their adoption in academic and large hospitals is slower than expected. This finding suggests a need for stronger management, communication, and educational efforts to promote biosimilar uptake in public hospitals.
📢Latest update on the NHI! 📢 Dive into our latest piece on the judicial review of the South African National Health Insurance Bill. Learn about the intriguing case and its implications on the healthcare industry. 🏛️💼💡 #HealthcarePolicy #LegalReview #NationalHealthInsuranceBill
Discover the global perspective on orphan medicines and their role in treating rare diseases. Learn about the unique challenges and incentives in their development. 🌍💊 #OrphanMedicines #RareDiseases #HealthcareInnovation #RareDiseaseDay. Read more here
📚 New research findings alert! 🚨 A recent study shows that increasing coverage of maternal, child and inpatient services is associated with reduced poverty in low and middle-income countries. 💡 This supports pro-poor approaches towards Universal Health Coverage. 🌍 Let’s work together to ensure #HealthForAll and #EndPoverty. Read more here 📖 #UHC #GlobalHealth #HealthEquity
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.